QL1706/Bevacizumab Chemotherapy in Post-ICI Non-Squamous NSCLC
Status:
NOT_YET_RECRUITING
Trial end date:
2029-07-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate QL1706 plus bevacizumab with or without chemotherapy in patients with PD-L1-negative, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) previously treated with immune checkpoint inhibitors (ICIs). The primary objectives are:
To assess the efficacy and safety of QL1706 combined with bevacizumab ( chemotherapy) in this population.
Eligible patients with PD-L1-negative, locally advanced or metastatic non-squamous NSCLC who progressed after prior PD-1/PD-L1 inhibitor therapy will be assigned to one of two treatment arms at the investigator's discretion:
Arm 1: QL1706 + bevacizumab + chemotherapy (target enrollment: 67 subjects). Single-agent chemotherapy (selected from regimens not previously received) will be administered, with options including nab-paclitaxel, pemetrexed, or docetaxel.
Arm 2: QL1706 + bevacizumab (target enrollment: 10 subjects).